Reproducibility of Transcriptomic Signatures and Candidate Genes in Human Intervertebral Disc Degeneration: A Discovery–Validation Re-Analysis of Public Datasets

Purpose: Integrative analyses of public transcriptomic datasets are widely used to nominate hub genes and therapeutic targets in intervertebral disc degeneration (IVDD), but whether such candidates replicate across datasets is rarely tested. We assessed the reproducibility of gene- and pathway-level signatures of IVDD using a discovery–validation design. Methods:Six Gene Expression Omnibus (GEO) series used in an overlap-and-network pipeline (four degeneration-versus-control comparisons and two cell-type or intervention contrasts) were re-analysed dataset by dataset (limma or DESeq2, with design adjustment where needed). Thirty-three candidate genes from that pipeline were audited, and a weighted Stouffer meta-analysis of the four discovery datasets was tested for replication in three independent validation cohorts (GSE70362, 48 samples from 18 donors; the non-overlapping samples of GSE23130; GSE34095). We also quantified genome-wide agreement between datasets, checked sample uniqueness, performed pre-ranked gene set enrichment analysis (Hallmark and Reactome) and analysed a combined protein–protein interaction network. Results:Samples 1–15 of GSE23130 were the specimens of GSE15227, and 23 PubMed Central articles cite both accessions. Genome-wide agreement between degeneration datasets was negligible (Spearman ρ −0.13 to 0.13). Of 1252 genes significant in the discovery meta-analysis, 49% changed in the same direction in validation (binomial p = 0.78); 15 replicated and two remained robust to leave-one-dataset-out analysis. None of the 33 candidates replicated robustly; ACAN, COL9A3 and COL11A2 changed significantly in the opposite direction in validation, and the apparent downregulation of MMP3 and MMP9 arose only from non-degeneration contrasts. A reproducible overlap step selected 14 mainly interferon-related genes driven by these contrasts. At the pathway level, E2F target and G2-M checkpoint (proliferation) gene sets were enriched in both meta-analyses and had positive enrichment scores in all nine datasets, whereas inflammatory and TNF-α/NF-κB signatures did not replicate. Conclusions:Gene-level IVDD signatures derived from small public datasets are not reproducible, and overlap-based hub genes should not be presented as therapeutic targets without independent validation. Within the datasets examined, a cell proliferation programme was the most consistent pathway-level signal; whether it is a feature of disc degeneration requires experimental validation. We provide a checklist for future secondary analyses of IVDD transcriptomes.

Authors

Institutions

Publication Details

Journal
Current Issues in Molecular Biology
Published
2026-11-16
DOI
https://doi.org/10.3390/cimb48111236
Primary Topic
Spine and Intervertebral Disc Pathology
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Reproducibility of Transcriptomic Signatures and Candidate Genes in Human Intervertebral Disc Degeneration: A Discovery–Validation Re-Analysis of Public Datasets

Ramya Lakshmi Rajendran, Prakash Gangadaran, Khan Sharun, Girinivasan Chellamuthu et al.
3 links
Current Issues in Molecular Biology
Spine and Intervertebral Disc Pathology
article

Reproducibility of Transcriptomic Signatures and Candidate Genes in Human Intervertebral Disc Degeneration: A Discovery–Validation Re-Analysis of Public Datasets

Ramya Lakshmi Rajendran, Prakash Gangadaran, Khan Sharun, Girinivasan Chellamuthu, Sathish Muthu, Byeong‐Cheol Ahn, Muruganantham Bharathi, Sridhar Muthusami, Kaviyaprabha Rangaraj, Yogavalli Madhavan
article en

Abstract

Purpose: Integrative analyses of public transcriptomic datasets are widely used to nominate hub genes and therapeutic targets in intervertebral disc degeneration (IVDD), but whether such candidates replicate across datasets is rarely tested. We assessed the reproducibility of gene- and pathway-level signatures of IVDD using a discovery–validation design. Methods:Six Gene Expression Omnibus (GEO) series used in an overlap-and-network pipeline (four degeneration-versus-control comparisons and two cell-type or intervention contrasts) were re-analysed dataset by dataset (limma or DESeq2, with design adjustment where needed). Thirty-three candidate genes from that pipeline were audited, and a weighted Stouffer meta-analysis of the four discovery datasets was tested for replication in three independent validation cohorts (GSE70362, 48 samples from 18 donors; the non-overlapping samples of GSE23130; GSE34095). We also quantified genome-wide agreement between datasets, checked sample uniqueness, performed pre-ranked gene set enrichment analysis (Hallmark and Reactome) and analysed a combined protein–protein interaction network. Results:Samples 1–15 of GSE23130 were the specimens of GSE15227, and 23 PubMed Central articles cite both accessions. Genome-wide agreement between degeneration datasets was negligible (Spearman ρ −0.13 to 0.13). Of 1252 genes significant in the discovery meta-analysis, 49% changed in the same direction in validation (binomial p = 0.78); 15 replicated and two remained robust to leave-one-dataset-out analysis. None of the 33 candidates replicated robustly; ACAN, COL9A3 and COL11A2 changed significantly in the opposite direction in validation, and the apparent downregulation of MMP3 and MMP9 arose only from non-degeneration contrasts. A reproducible overlap step selected 14 mainly interferon-related genes driven by these contrasts. At the pathway level, E2F target and G2-M checkpoint (proliferation) gene sets were enriched in both meta-analyses and had positive enrichment scores in all nine datasets, whereas inflammatory and TNF-α/NF-κB signatures did not replicate. Conclusions:Gene-level IVDD signatures derived from small public datasets are not reproducible, and overlap-based hub genes should not be presented as therapeutic targets without independent validation. Within the datasets examined, a cell proliferation programme was the most consistent pathway-level signal; whether it is a feature of disc degeneration requires experimental validation. We provide a checklist for future secondary analyses of IVDD transcriptomes.

Current Issues in Molecular BiologyVol. 48(11)
Vinayaka Missions University (IN), Aarupadai Veedu Medical College & Hospital (IN), Kyungpook National University Hospital (KR), Kyungpook National University (KR), Orthopaedic Research Group (IN), Karpagam Academy of Higher Education (IN), Yuan Ze University (TW)
Karpagam Academy of Higher Education
Good health and well-being
Spine and Intervertebral Disc Pathology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon